RA Biologics Lower COVID-19 Deaths, but Not Recovery Time
Do abatacept, cenicriviroc, or infliximab improve time to recovery for patients hospitalized with COVID-19 pneumonia compared with standard care?
News
Baricitinib Effective in JIA Subsets
A phase 3 trial assessed a selective Janus kinase 1/2-inhibitor, baricitinib, in patients with juvenile idiopathic arthritis (JIA), demonstrating it's efficacy and safety compared to placebo.
GCA and the Risk of Cerebrovascular Ischemic Events
Cerebrovascular ischemic events (CIE) can be one of the most severe complications of giant cell arteritis (GCA), but is seen in 4-5% of GCA patients according to a recent French University Hospital.
Upadacitinib Outcomes in High Risk RA Patients
A safety analysis of six phase III SELECT trials showed that higher-risk rheumatoid arthritis (RA) patients had an increased risk of MACE, malignancy (excluding NMSC) and venous thromboembolic events (VTE) regardless of being treated with either upadacitinib (UPA) or adalimumab (ADA).
ICYMI: ChatGPT - A Boon or Threat to Scientific Publication?
ChatGPT is a new, artificial intelligence chatbot that has dramatically changed the digital worlds of education, research, graphic design, statistics and more. While this AI driven platform has the untold potential in generating written content, there is considerable concern in assuring that human-generated content of research, education and publishing has veracity.
ICYMI: LAVLI - A New Autoinflammatory Disorder
NIH researchers have have described a novel autoinflammatory disorder called "Lyn kinase-associated vasculopathy and liver fibrosis" (LAVLI), based on a mutation in the LYN gene (that encodes the Lyn kinase protein). They discovered that increased Lyn kinase activity promotes systemic inflammation, by altering microvascular permeability and neutrophil recruitment, while at the same time promoting hepatic fibrosis.
ICYMI: Drug Safety Differences with New Novel Therapies in RA
Safety outcomes for targeted synthetic or biological disease-modifying antirheumatic drugs (b/ts DMARDs) used to treat RA were studied using data from the Anti-Rheumatic Therapies in Sweden (ARTIS) registry, showing that these newer agents are largely similar, but still have particular differences for specific infection or other adverse event risks.
ICYMI: Hydroxychloroquine Dose and Risk for Incident Retinopathy
A cohort study in Annals of Internal Medicine shows that higher hydroxychloroquine doses was associated with progressively greater risk for incident retinopathy. The study aimed to assess the long-term risk for incident hydroxychloroquine retinopathy and examine the degree to which average hydroxychloroquine dose within the first 5 years of treatment predicts this risk.
ICYMI: GRAPPA Recommendations for Treating Enthesitis in Psoriatic Arthritis
GRAPPA has provided new, evidence based updates to the management of enthesitis in patients with psoriatic arthritis (PsA), affecting at least 30% of PsA patients and is associated with more severe disease, x-ray damage, and poorer outcomes.
ICYMI: 25 Great Women in Rheumatology
I reached out to many leaders in rheumatology and asked: who are the great women in rheumatology who should be recognized? This was prompted by a smart article in Annals of Rheumatic Disease written by Drs. Tuhina Neogi (Boston) and Nicola Dalbeth (N. Zealand), entitled "Where are the women ‘Heroes and Pillars of Rheumatology’?
ICYMI: Carpal Tunnel - Steroid injection vs. Night Splinting
A prospective, pragmatic, open-label, randomized trial conducted by the UK National Health Service, studied interventions in patients with carpal tunnel syndrome (CTS) and found no advantage to either CTS corticosteroid injection (CSI) or night splinting (NS) as the initial treatment of CTS.
